Unicycive Therapeutics Inc (NASDAQ:UNCY) does about 894.44K shares in volume on a normal day but saw 2867089 shares change hands in the recent trading day. The company now has a market cap of 79.90M USD. Its current market price is $0.66, marking an increase of 13.08% compared to the previous close of $0.59. The 52 week high reached by this stock is $0.96 whilst the lowest price level in 52 weeks is $0.20.
The consensus objective for the share price is $6.29, suggesting that the stock has a potential upside of 89.51% over the period.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 21, 2025 when Guggenheim initiated the stock to “Buy” and issued a price target of $6.
The current price level is 11.76%, 11.28%, and 20.65% away from its SMA20, SMA50, and SMA200 respectively, with the UNCY price moving below the 50-day SMA on current market day. Unicycive Therapeutics Inc (UNCY) stock is up 19.74% over the week and 1.91% over the past month. Its price is -16.60% year-to-date and -21.14% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.07 and -0.15 for whole year. Expected sales for next quarter are $4.14M, which analysts say will come at $22.58M for the current fiscal year and next year at $348.71M.
To reach the target analysts have set, the stock logically needs to grow 89.51 percent from here.
Outstanding shares total 119.75M with insiders holding 5.22% of the shares and institutional holders owning 52.50% of the company’s common stock. The company has a return on investment of -195.79% and return on equity of -2355.27%. The forward price to earnings ratio is 0.65. The beta has a value of 2.00. Price to book ratio is 7.04.
